You are here

Aminomethyl benzamides as novel anti Ebola agents

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41AI126971-01
Agency Tracking Number: R41AI126971
Amount: $727,199.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NIAID
Solicitation Number: PA15-270
Timeline
Solicitation Year: 2015
Award Year: 2016
Award Start Date (Proposal Award Date): 2016-08-01
Award End Date (Contract End Date): 2019-07-31
Small Business Information
2242 WEST HARRISON SUITE 201, Chicago, IL, 60612-3515
DUNS: 079936940
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 LIJUN RONG
 (312) 355-0203
 lijun@uic.edu
Business Contact
 LIA LIU
Phone: (630) 915-4575
Email: lia.liu@chicagobiosolutions.com
Research Institution
 UNIVERSITY OF ILLINOIS AT CHICAGO
 1737 W POLK ST STE 310
CHICAGO, IL, 60612-7224
 Nonprofit college or university
Abstract
Ebola EBOV and Marburg MARV viruses belong to the family Filoviridae and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction with an incubation period of days Because of the safety concerns these viruses are designated as the biosafety level agents Currently there is no effective vaccine or therapeutic treatment against filoviral infection and pathogenesis in humans Africa has recently suffered a lethal EBOV epidemic with people infected and deaths underscoring the urgency of antiviral drug discovery and development This application defines a plan to develop potent small molecule inhibitors which block entry of EBOV We have identified compounds that inhibit entry of infectious EBOV MARV IC values M These hit compounds exhibit selectivity for EBOV MARV entry The overall objective of this Phase I application is to develop these inhibitors as potential anti EBOV therapeutics This application will focus on the following three specific aims Synthesize structurally diverse analogs of the anti Ebola CBS hit series based on structure activity relationships SARs to improve potency and selectivity Validate the lead inhibitor candidates in the infectious assay and investigate the mechanism of action MOA of the EBOV inhibitors Select EBOV inhibitors with in vitro ADME properties suitable for i v and oral dosing Project Narrative This project is to discover and develop small molecule entry inhibitors for Ebola viral infection The proposed research will help to develop potential antiviral therapeutics

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government